Cited 0 times in
The validation of the dual antiplatelet therapy score in East Asians receiving percutaneous coronary intervention with exclusively second generation drug-eluting stents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김민관 | - |
dc.date.accessioned | 2021-12-28T17:55:36Z | - |
dc.date.available | 2021-12-28T17:55:36Z | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 1522-1946 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187332 | - |
dc.description.abstract | Objectives: We investigated whether the dual antiplatelet therapy (DAPT) score (DS) predicts clinical outcome in an East-Asian population that received exclusively second generation drug-eluting stent (DES). Backgrounds: It is uncertain whether the DS could adequately risk stratify patients exclusively receiving second generation DES. Methods: From the Grand-DES registry, we evaluated patients who were treated with DAPT for at least 12 months and were event-free at 12 months after DES implantation. Patients were classified into two categories: high DS (≧2) (n = 3,157); and low DS (<2) (n = 5,226). The primary ischemic outcome was a composite of stent thrombosis and all myocardial infarction (MI), and the primary bleeding outcome was TIMI major or minor bleeding. A propensity score (PS)-matched analysis was done to correct for baseline differences between extended DAPT group and the conventional group. Results: Among 8,383 subjects, the primary ischemic outcome occurred in 48 patients (0.6%) and the primary bleeding outcome in 49 patients (0.6%). High DS was associated with a higher incidence of ischemic events (ischemic outcome: 0.8% vs. 0.4%, for high vs. low DS, Log-rank p = .039), but not with any differences in bleeding events (Log-rank p = .734). In the PS-matched analysis, extended group was associated with lower risk of composite endpoint of MI, stent thrombosis, or cardiac death in only the high DS group (1.8% vs. 3.7%, Log-rank p = .004; hazard ratio 0.45, 95% confidence interval 0.27-0.76; p = .003 after adjustment). Conclusions: The DS was an adequate risk stratifier for future ischemic events in East Asians receiving exclusively second generation DES. Trial registration: ClinicalTrials.gov NCT03507205. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Liss | - |
dc.relation.isPartOf | CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Asian Continental Ancestry Group | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Drug-Eluting Stents* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Percutaneous Coronary Intervention* / adverse effects | - |
dc.subject.MESH | Platelet Aggregation Inhibitors / adverse effects | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | The validation of the dual antiplatelet therapy score in East Asians receiving percutaneous coronary intervention with exclusively second generation drug-eluting stents | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Minkwan Kim | - |
dc.contributor.googleauthor | Kyung Woo Park | - |
dc.contributor.googleauthor | Hak Seung Lee | - |
dc.contributor.googleauthor | You-Jeong Ki | - |
dc.contributor.googleauthor | Jeehoon Kang | - |
dc.contributor.googleauthor | Chee-Hoon Kim | - |
dc.contributor.googleauthor | Jung-Kyu Han | - |
dc.contributor.googleauthor | Han-Mo Yang | - |
dc.contributor.googleauthor | Hyun-Jae Kang | - |
dc.contributor.googleauthor | Bon-Kwon Koo | - |
dc.contributor.googleauthor | Hyo-Soo Kim | - |
dc.identifier.doi | 10.1002/ccd.29682 | - |
dc.contributor.localId | A05957 | - |
dc.relation.journalcode | J00471 | - |
dc.identifier.eissn | 2451-9456 | - |
dc.identifier.pmid | 33817960 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1002/ccd.29682 | - |
dc.subject.keyword | blood platelets | - |
dc.subject.keyword | percutaneous coronary intervention | - |
dc.subject.keyword | platelet aggregation inhibitors | - |
dc.subject.keyword | thrombosis | - |
dc.subject.keyword | validation study | - |
dc.contributor.alternativeName | Kim, Minkwan | - |
dc.contributor.affiliatedAuthor | 김민관 | - |
dc.citation.volume | 98 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | E332 | - |
dc.citation.endPage | E341 | - |
dc.identifier.bibliographicCitation | CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol.98(3) : E332-E341, 2021-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.